Werewolf Therapeutics SEC filings document material events, operating results, governance matters, and capital-structure disclosures for a Delaware biopharmaceutical company developing conditionally activated immune therapeutics. Recent 8-K filings furnish quarterly financial results, press-release exhibits, and updates tied to the company’s PREDATOR, INDUKINE, and INDUCER programs.
The filings also cover Nasdaq continued-listing matters, audit committee composition, exit and disposal activities, emerging growth company status, common stock registered under the HOWL symbol, shareholder voting matters, clinical and regulatory disclosures, and risk language related to strategy, operations, development plans, and corporate alternatives.
Werewolf Therapeutics, Inc. director Luke Evnin reported three indirect open-market sales of Common Stock by affiliated investment entities. Across May 18–20, 2026, these entities sold a total of 171,049 shares at reported weighted average prices of $0.50, $0.45 and $0.43 per share. The trades were effected under a Rule 10b5-1 trading plan dated March 26, 2026. After these sales, the affiliated entities together held 955,447 shares, and Evnin disclaims beneficial ownership beyond his pecuniary interest.
RA Capital Management and affiliated funds report beneficial ownership of 6,116,140 shares of Werewolf Therapeutics common stock, equal to 12.6% of the company, based on 48,596,817 shares outstanding as of May 1, 2026. Most of these shares, 5,709,858 or 11.7% of the class, are held by RA Capital Healthcare Fund, with the balance held by RA Capital Nexus Fund II. RA Capital has delegated voting and investment authority over the funds’ holdings and may be deemed a beneficial owner for Section 13(d) purposes, while the funds themselves disclaim beneficial ownership. The amendment also details recent open market sales by the Fund and Nexus Fund II from May 8 to May 12, 2026 at weighted average prices between $0.64 and $0.71 per share, and notes that the reported ownership percentages reflect an increase in the issuer’s outstanding shares.
Werewolf Therapeutics director-affiliated entities reported an open-market sale of company stock. Entities associated with Luke Evnin sold 44,679 shares of Werewolf Therapeutics common stock at a weighted average price of $0.54 per share in an open-market transaction. The sale was executed on May 13, 2026 under a pre-arranged Rule 10b5-1 trading plan dated March 26, 2026. After this transaction, these entities collectively held 1,126,496 shares indirectly, allocated among several MPM investment vehicles. Evnin disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.
Werewolf Therapeutics’ major MPM-affiliated investors filed Amendment No. 7 to Schedule 13D updating their ownership in the company’s common stock. The filing shows various MPM funds and related entities holding individual stakes ranging from 0.1% to 3.8% of outstanding shares.
As of May 1, 2026, the ownership percentages are calculated against 48,596,817 shares of Werewolf Therapeutics common stock. The reporting group sold blocks of shares in open-market transactions between May 6 and May 12, 2026 at average prices generally around $0.63–$0.70 per share.